TherapeuticsMD
TXMD
TXMD
117 hedge funds and large institutions have $821M invested in TherapeuticsMD in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
117
Holders Change
-21
Holders Change %
-15.22%
% of All Funds
2.92%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
54
Reduced
33
Closed
30
Calls
$4.48M
Puts
$1.68M
Net Calls
+$2.8M
Net Calls Change
+$1.11M
Top Buyers
| 1 |
Bank of New York Mellon
New York
|
+$13.6M |
| 2 |
JPMorgan Chase & Co
New York
|
+$10.3M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$8.56M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$3.91M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.07M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$24.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.6M |
| 5 |
Millennium Management
New York
|
-$6.06M |
